Dr. Xiaosong Meng, MD, PhD

Dr. Meng practices at University of Texas Southwestern Medical Center at Dallas in Frisco, Texas.

Dr. Meng's NPI, 1003227802, was assigned on May 14, 2014. Dr. Meng graduated from New York University School of Medicine in 2014. Dr. Meng holds Texas license S0336.

Dr. Meng's primary practice is University of Texas Southwestern Medical Center at Dallas, at 12500 Dallas Pkwy, Frisco, TX 75033 in Denton County. The practice phone is (214) 645-0624.

Dr. Meng's primary practice is University of Texas Southwestern Medical Center at Dallas in Frisco, Texas. Dr. Meng is also affiliated with Texas Health Hospital Frisco. The medical group on file is University of Texas Southwestern Medical Center. Dmand AI also links Dr. Meng to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Meng practices, 2 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Meng's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Meng is board certified in urology by the American Board of Urology. Dr. Meng is licensed in Texas.

Dmand AI lists bladder removal, enlarged prostate, enlarged prostate transurethral surgery (TURP), kidney cysts, kidney removal surgery, prostate cancer, prostate surgery and transurethral procedures among the conditions Dr. Meng treats.

CMS data shows 1,742 Medicare services from Dr. Meng across 16 procedure codes in 2024, for 313 Medicare patients. Medicare paid $54,300 for them.

CMS counts 313 Medicare patients who saw Dr. Meng in 2024. The largest group is 65 to 74, with 178 patients. 75% of them have cancer, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.32, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Meng's median patient age at 70, with 9% women.

In 2024, Dr. Meng wrote 321 Medicare Part D claims for 128 patients. 93% of them were for generic drugs. CMS names the drug for 227 of them, across 7 drugs with 11 or more claims each, at $3,799 in total drug cost. In 2023, CMS named 161 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Meng for performance year 2024, reported as part of a group. Dr. Meng accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Meng as offering telehealth.

Hernia repair (minimally invasive): 1 to 10 procedures (CMS shows small counts as a range)

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 68 papers to Dr. Meng, published from 2012 to 2025. 2020 was the busiest year, with 12. The most frequent topics are Prostatic Neoplasms, Image-Guided Biopsy and Magnetic Resonance Imaging. Dr. Meng has published most often in Urol Oncol. Dr. Meng's most frequent co-authors are Vitaly Margulis, MD, Solomon Lukasz Woldu, MD and Aditya Bagrodia, MD.

Dmand AI links Dr. Meng to 1 clinical trial. 1 is still active or recruiting.

CMS Open Payments shows 112 general payments to Dr. Meng from 33 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 56% of the total. Profound Medical Corp. paid the most, $7,681.

Dmand AI lists 1 award for Dr. Meng.

Dr. Meng graduated from New York University School of Medicine in 2014.

Dr. Meng is in network with 19 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. HMO plans come from the most carriers, 11. Check the plan with the practice before a visit.